Xeris Biopharma Holdings (XERS) has drawn attention after recent share price pressure, with the stock down over the month and past 3 months, despite positive annual revenue and net income growth figures.

At a latest share price of US$6.12, Xeris Biopharma’s weaker recent share price returns over the past month and quarter contrast with a much stronger 1 year and 3 year total shareholder return. This suggests that momentum has cooled after a very large multi year gain as investors reassess the balance of growth potential and risks.

If this recent pullback has you reviewing the sector, it could be a good moment to see what else is on the move with our screener of 27 healthcare AI stocks.

So with Xeris Biopharma posting annual revenue and net income growth, yet trading around US$6.12 and at a wide discount to the average analyst price target, is this pullback a genuine opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 45.1% Undervalued

With Xeris Biopharma’s fair value narrative sitting at about $11.14 per share against a last close of $6.12, the current pullback looks very different once you factor in what the most followed storyline expects from revenue, margins, and cash generation over the next few years.

Persistent high gross margins, alongside scaling sales of Gvoke, Recorlev, and Keveyis, set the stage for operational leverage and sustainable EBITDA and net margin improvements as revenue expands and expense ratios decline over time.

Curious what kind of revenue trajectory, margin lift, and profit multiple are baked into that fair value estimate, and how much growth XP-8121 is expected to carry on its shoulders, together with the existing endocrine portfolio? The full narrative spells out those assumptions in detail.

Result: Fair Value of $11.14 (UNDERVALUED)

However, that story could change quickly if XP-8121 stumbles in trials or if rising R&D and SG&A costs outpace revenue and keep net income under pressure.

Next Steps

If this mix of optimism and caution around Xeris Biopharma has you thinking, it is worth checking the underlying data yourself and forming a view. To help you weigh both sides quickly, take a look at the balance of 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you are reassessing Xeris Biopharma, this is also a smart time to widen your watchlist and compare it with other opportunities using focused screeners.

• Spot potential bargains early by scanning our list of screener containing 24 high quality undiscovered gems that combine solid fundamentals with lower market attention.
• Strengthen your income plan by reviewing 15 dividend fortresses, a set of companies offering higher yields that could complement a growth focused portfolio.
• Prioritise resilience by checking 77 resilient stocks with low risk scores, featuring businesses with lower risk scores that may help balance more volatile positions.

Take a few minutes now to compare these ideas against your current holdings so you are not looking back later wishing you had broadened your search earlier.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.